Catalent, Inc. (NYSE: CTLT), a Somerset, N.J.-based provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, acquired MaSTherCell Global, Inc., a technology-focused cell and gene therapy contract development and manufacturing organization to cell therapy innovators, for an aggregate of $315m in cash, subject to a customary adjustments.
MaSTherCell extends Catalent’s leadership position in the biotech industry, complementing its gene therapy offering, and allowing them to deliver comprehensive development, manufacturing, analytical, fill-finish, and clinical supply solutions for innovators across the large molecule space.
Upon completion of the transaction, which is expected in the current, third quarter of Catalent’s 2020 fiscal year and is subject to customary closing conditions, MaSTherCell’s 240 employees, including its leadership team, will become part of the Catalent Biologics business.
Founded in 2011 and led by Darren Head, Chief Executive Officer, MaSTherCell has a 25,000 square-foot facility in Gosselies, Belgium providing clinical services, and construction is in progress on a dedicated 60,000 square-foot adjacent commercial-scale production and fill-finish facility, which is scheduled to open in the fall of 2021 and add over 250 new jobs to the current team of over 240. Its 32,000 square-foot U.S. facility in Houston, Texas, upon completion of validation activities, will focus on development-scale projects and will employ a team of over 50 experts before the end of the year. The company’s experience includes therapies based on chimeric antibody receptor-engineered T cells (CAR-T), T cell receptors (TCR), tumor-infiltrating lymphocytes (TIL), and mesenchymal stem cells (MSC). MaSTherCell Global is backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. (NASDAQ:ORGS).
Led by John Chiminski, Chair & Chief Executive Officer, Catalent is a global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. The company employs over 13,000 people, including over 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue.
FinSMEs
03/02/2020